Entera Bio (ENTX) AI Stock Analysis

• Market Cap: $64.20M
• Dividend Yield: N/A
• Average Volume (3M): 123.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: 25.25%
• EPS Growth: 5.96%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 45,857,243
• 10 Day Avg. Volume: 240,874
• 30 Day Avg. Volume: 123,776
• PEG Ratio: 0.43
• Price to Book (P/B): 9.88
• Price to Sales (P/S): 440.99
• P/FCF Ratio: -11.70
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 516.87
• Enterprise Value/Gross Profit: -8.01K
• Enterprise Value/Ebitda: -5.97
• 1Y Price Target: $10.00
• Price Target Upside: 532.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.00 ▼(-36.71% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is held back primarily by weak financial performance (minimal/declining revenue, persistent losses, and cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting support comes from low leverage/improved equity and positive corporate developments (expanded OPKO collaboration and FDA Phase 3 agreement), while valuation signals are limited due to negative earnings and no dividend.

Positive Factors

Strategic partnership expansion

The expanded OPKO collaboration creates durable R&D and funding capacity by sharing 50% ownership and development costs for the LA‑PTH program. Joint ownership aligns incentives, reduces Entera’s single‑party cash burden, and accelerates development scale and regulatory readiness over the next 2–6 months and beyond.

Regulatory progress for lead asset

FDA agreement for a Phase 3 EB613 program and the broad qualification of BMD as an endpoint materially de‑risk the clinical pathway. This regulatory clarity supports a viable pivotal trial design, increases likelihood of efficient approval timeline, and preserves the commercial opportunity for an oral osteoporosis therapy.

Low leverage and stronger equity base

Very low debt levels and a materially larger equity base reduce short‑term liquidity risk and limit forced financing needs. This structural balance sheet strength gives management flexibility to pursue clinical milestones or partnerships without immediate leverage constraints, supporting multi‑quarter R&D execution.

Negative Factors

Minimal and declining revenue

Persistent minimal revenue emphasizes Entera’s current reliance on R&D milestones and partnerships rather than product sales. Over the next several quarters this limits internal cash generation, increases dependency on external funding or alliances, and raises execution risk if trials delay or partnerships change.

Sustained negative cash flow

Ongoing cash burn near $7M annually is structural for a development biotech and will require further financing or partner funding to sustain pivotal trials. Even with some improvement versus prior year, continued negative FCF elevates dilution and execution risk if capital markets or partner commitments tighten over the medium term.

Negative returns and ongoing losses

Deep and persistent operating losses with negative ROE indicate ongoing value erosion absent successful clinical outcomes or commercialization. Over multiple quarters this increases the probability of equity dilution, constrains reinvestment capacity, and could pressure strategic options if trial results or approvals are delayed.

Entera Bio Business Overview & Revenue Model

Company Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

How the Company Makes Money

Entera Bio generates revenue through the development and commercialization of its proprietary oral drug formulations. The company's key revenue streams include collaborations and licensing agreements with other pharmaceutical companies. These partners may provide upfront payments, milestone payments, and royalties based on the sales of successfully developed drugs. Entera Bio's business model relies heavily on research and development activities, strategic partnerships, and the potential commercialization of its pipeline products.

Entera Bio Financial Statement Overview

Summary

Financials reflect a development-stage biotech: very small and declining TTM revenue ($0.12M, ~-25%), sizable ongoing losses (EBIT about -$10.8M) and negative ROE (~-16.7%), plus continued cash burn (operating/FCF about -$7.3M TTM). Offsetting strengths are low leverage (debt-to-equity ~0.014) and improved equity versus 2024, which reduces near-term balance-sheet risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small ($0.12M) and down ~25% versus the prior period, highlighting limited commercial traction. Profitability remains weak with large operating losses (EBIT about -$10.8M) and deeply negative net margins, though losses appear directionally improved versus 2024 annual results (net loss ~$10.8M TTM vs. ~$9.5M in 2024, with margins less extreme due to the small revenue base). Overall, the income profile reflects a development-stage biotech with persistent losses and volatile margins driven by low revenue.

Balance Sheet

Leverage is low, with modest total debt ($0.21M TTM) and a very low debt-to-equity ratio (~0.014), which reduces financial risk. Equity has increased materially versus 2024 (about $15.2M TTM vs. $8.1M in 2024), supporting the balance sheet. The key weakness is continued negative returns on equity (about -16.7% TTM), indicating ongoing value dilution risk if losses persist.

Cash Flow

Cash burn remains significant: operating cash flow is about -$7.3M TTM and free cash flow about -$7.3M TTM, consistent with a company still funding operations rather than generating cash. A positive point is that free cash flow burn improved versus 2024 (roughly -$7.3M TTM vs. about -$6.8M in 2024 annual, with reported free cash flow growth positive TTM), but the business is still structurally cash-flow negative. Cash conversion versus net loss is relatively close (free cash flow roughly 85% of the net loss TTM), suggesting losses are largely cash-based rather than purely accounting-driven.

Breakdown	TTM	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	124.00K	181.00K	0.00	134.00K	571.00K	365.00K
Gross Profit	-8.00K	9.00K	-56.00K	-31.00K	198.00K	65.00K
EBITDA	-10.73M	-9.54M	-8.80M	-12.87M	-12.16M	-11.11M
Net Income	-10.78M	-9.54M	-8.89M	-13.07M	-12.19M	-11.22M
Balance Sheet
Total Assets	17.41M	9.39M	11.77M	13.13M	25.99M	9.72M
Cash, Cash Equivalents and Short-Term Investments	8.57M	8.66M	11.02M	12.31M	24.89M	8.59M
Total Debt	211.00K	272.00K	390.00K	91.00K	302.00K	432.00K
Total Liabilities	2.17M	1.31M	1.38M	1.37M	3.42M	2.21M
Stockholders Equity	15.23M	8.08M	10.39M	11.75M	22.57M	7.51M
Cash Flow
Free Cash Flow	-7.34M	-6.82M	-7.33M	-12.55M	-9.08M	-10.61M
Operating Cash Flow	-7.26M	-6.82M	-7.31M	-12.50M	-9.06M	-10.56M
Investing Cash Flow	-86.65K	-3.00K	-17.00K	-102.00K	-17.00K	-53.00K
Financing Cash Flow	17.37M	4.48M	6.04M	13.00K	25.38M	4.05M

Entera Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Neutral. The current price of 1.58 is above the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.63, and below the 200-day MA of 2.00, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 54.04 is Neutral, neither overbought nor oversold. The STOCH value of 68.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENTX.

Entera Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EQ	50 Neutral	$103.52M	-2.88	-90.24%	―	-90.43%	-382.07%
ENTX	47 Neutral	$64.20M	-5.81	-99.43%	―	25.25%	5.96%
ATYR	46 Neutral	$97.42M	-1.26	-103.22%	―	-19.15%	10.90%
NRXP	46 Neutral	$56.57M	-0.78	―	―	―	-9.32%
PLRX	42 Neutral	$76.81M	-0.45	-64.27%	―	―	14.19%

Entera Bio Corporate Events

Entera Bio Expands OPKO Partnership, Adds New Director

On February 3, 2026, Entera Bio and OPKO Health broadened their 2025 collaboration and license agreement to add joint preclinical and clinical development of a once-daily long-acting PTH (LA-PTH) oral tablet for hypoparathyroidism and other indications, with the parties sharing both ownership and development costs for this new program. The expanded deal leaves the economics of their ongoing oral oxyntomodulin program unchanged and follows encouraging pharmacodynamic and pharmacokinetic data reported in December 2025, positioning Entera more firmly in the race to offer an oral alternative to injectable PTH replacement and dual GLP-1/glucagon therapies in a market currently served by daily or weekly injections. Governance changes accompanied the strategic move: on January 29, 2026, director Gerald Ostrov tendered his resignation effective February 1, 2026, and the board appointed OPKO executive Steven D. Rubin as an independent Class III director and audit committee chairman from the same date, reinforcing OPKO’s strategic alignment with Entera while adding an experienced capital markets and biotech governance figure to oversee the expanded partnership.

The most recent analyst rating on (ENTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.

Entera Bio Reports Q3 2025 Results and FDA Agreement

Entera Bio announced its third quarter 2025 financial results and business updates, highlighting significant progress in its oral peptide therapies. The company received FDA agreement for its EB613 Phase 3 study, marking a pivotal step in osteoporosis treatment. Phase 2 data showed promising efficacy in younger post-menopausal women, and preclinical data for oral GLP-2 and OXM programs were presented at major conferences. Financially, Entera reported a net loss of $3.2 million for the quarter, with cash reserves expected to support operations into mid-2026.

The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.